NCT04491006View on ClinicalTrials.gov

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

May 20, 2022

Study Completion Date

May 20, 2022

Conditions
Alzheimer DiseaseDementia of Alzheimer Type
Interventions
DRUG

ATH-1017

Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe

DRUG

Placebo

Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe

Trial Locations (13)

2010

St Vincent's Centre for Applied Medical Research, Translational Research Centre, Darlinghurst

2065

Hammondcare Greenwich Hospital, Greenwich

2113

KaRa MINDS, Macquarie Park

2261

Central Coast Neurosciences Research, Central Coast

3144

HammondCare, Malvern

6009

Australian Alzheimer's Research Organization, Nedlands

12208

Neurological Associates of Albany, Albany

30030

iResearch Atlanta, Decatur

33407

Premiere Research Institute, West Palm Beach

92705

Syrentis Clinical Research, Santa Ana

97225

Center for Cognitive Health, Portland

98034

Evergreen Health Research Program, Kirkland

98104

University of Washington, Seattle

Sponsors

Lead Sponsor

Athira Pharma
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Athira Pharma

INDUSTRY

NCT04491006 - A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter